Skip to main page content

• HOME
• Current
• Archive
• Feedback
• Subscribe
• Help

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by ROBSON, P. Search for Related Content PubMed PubMed Citation Articles by ROBSON, P.

Therapeutic aspects of cannabis and cannabinoids

Warneford Hospital, Oxford OX3 7JX

Declaration of interest Funding from DOH. Between writing this paper and its acceptance for publication, P.R. was appointed Medical Director of GW Pharmaceuticals.

See editorial, p. 98, this issue.

ABSTRACT

Background Review commissioned in 1996 by the Department of Health (DOH).

Aims Assess therapeutic profile of cannabis and cannabinoids.

Method Medline search, references supplied by DOH and others, and personal communications.

Results and Conclusions Cannabis and some cannabinoids are effective anti-emetics and analgesics and reduce intra-ocular pressure. There is evidence of symptom relief and improved well-being in selected neurological conditions, AIDS and certain cancers. Cannabinoids may reduce anxiety and improve sleep. Anticonvulsant activity requires clarification. Other properties identified by basic research await evaluation. Standard treatments for many relevant disorders are unsatisfactory. Cannabis is safe in overdose but often produces unwanted effects, typically sedation, intoxication, clumsiness, dizziness, dry mouth, lowered blood pressure or increased heart rate. The discovery of specific receptors and natural ligands may lead to drug developments. Research is needed to optimise dose and route of administration, quantify therapeutic and adverse effects, and examine interactions.

This article has been cited by other articles:

				P. Fusar-Poli, J. A. Crippa, S. Bhattacharyya, S. J. Borgwardt, P. Allen, R. Martin-Santos, M. Seal, S. A. Surguladze, C. O'Carrol, Z. Atakan, et al. Distinct Effects of {Delta}9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing Arch Gen Psychiatry, January 1, 2009; 66(1): 95 - 105. [Abstract] [Full Text] [PDF]

				M. J. Seamon, J. A. Fass, M. Maniscalco-Feichtl, and N. A. Abu-Shraie Medical marijuana and the developing role of the pharmacist Am. J. Health Syst. Pharm., May 15, 2007; 64(10): 1037 - 1044. [Abstract] [Full Text] [PDF]

				H.-J. Zhu, J.-S. Wang, J. S. Markowitz, J. L. Donovan, B. B. Gibson, H. A. Gefroh, and C. L. DeVane Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 850 - 857. [Abstract] [Full Text] [PDF]

				G. Gobbi, F. R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, M. Solinas, T. Cassano, M. G. Morgese, G. Debonnel, A. Duranti, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis PNAS, December 20, 2005; 102(51): 18620 - 18625. [Abstract] [Full Text] [PDF]

				J. I. Sirven and A. T. Berg Marijuana as a treatment for epilepsy and multiple sclerosis?: A "grass roots" movement Neurology, June 8, 2004; 62(11): 1924 - 1925. [Full Text] [PDF]

				M. C. Jockers-ScheruBl, U. Matthies, H. Danker-Hopfe, U. E. Lang, R. Mahlberg, and R. Hellweg Chronic Cannabis Abuse Raises Nerve Growth Factor Serum Concentrations in Drug-Naive Schizophrenic Patients J Psychopharmacol, December 1, 2003; 17(4): 439 - 445. [Abstract] [PDF]

				R. A. Gustafson, B. Levine, P. R. Stout, K. L. Klette, M.P. George, E. T. Moolchan, and M. A. Huestis Urinary Cannabinoid Detection Times after Controlled Oral Administration of {Delta}9-Tetrahydrocannabinol to Humans Clin. Chem., July 1, 2003; 49(7): 1114 - 1124. [Abstract] [Full Text] [PDF]

				L. Iversen Cannabis and the brain Brain, June 1, 2003; 126(6): 1252 - 1270. [Abstract] [Full Text] [PDF]

				I. J. Arinze and Y. Kawai Sp Family of Transcription Factors Is Involved in Valproic Acid-induced Expression of Galpha i2 J. Biol. Chem., May 9, 2003; 278(20): 17785 - 17791. [Abstract] [Full Text] [PDF]

				V. C. J. Wallace, D. F. Cottrell, P. J. Brophy, and S. M. Fleetwood-Walker Focal Lysolecithin-Induced Demyelination of Peripheral Afferents Results in Neuropathic Pain Behavior That Is Attenuated by Cannabinoids J. Neurosci., April 15, 2003; 23(8): 3221 - 3233. [Abstract] [Full Text] [PDF]

				S. Parmentier-Batteur, K. Jin, L. Xie, X. O. Mao, and D. A. Greenberg DNA Microarray Analysis of Cannabinoid Signaling in Mouse Brain in Vivo Mol. Pharmacol., October 1, 2002; 62(4): 828 - 835. [Abstract] [Full Text] [PDF]

				A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202. [Abstract] [Full Text] [PDF]

				A. R. MacQueen Pragmatic approach to the dangers of cannabis use The British Journal of Psychiatry, September 1, 2001; 179 (3): 270 - 271. [Full Text]

				M. FARRELL and B. RITSON Cannabis and health The British Journal of Psychiatry, February 1, 2001; 178(2): 98 - 98. [Full Text] [PDF]